State Key Laboratory for Zoonotic Diseases, Key Laboratory of Zoonosis Research of the Ministry of Education, the Institute of Zoonosis, and the College of Veterinary Medicine, Jilin University, Changchun, China.
PLoS Negl Trop Dis. 2023 Mar 27;17(3):e0011217. doi: 10.1371/journal.pntd.0011217. eCollection 2023 Mar.
Cryptosporidium parvum is a globally distributed zoonotic protozoan parasite that causes moderate to severe, sometime deadly, watery diarrhea in humans and animals, for which fully effective treatments are yet unavailable. In studying the mechanism of action of drugs against intracellular pathogens, it is important to validate whether the observed anti-infective activity is attributed to the drug action on the pathogen or host target. For the epicellular parasite Cryptosporidium, we have previously developed a concept that the host cells with significantly increased drug tolerance by transient overexpression of the multidrug resistance protein-1 (MDR1) could be utilized to evaluate whether and how much the observed anti-cryptosporidial activity of an inhibitor was attributed to the inhibitor's action on the parasite target. However, the transient transfection model was only applicable to evaluating native MDR1 substrates. Here we report an advanced model using stable MDR1-transgenic HCT-8 cells that allows rapid development of novel resistance to non-MDR1 substrates by multiple rounds of drug selection. Using the new model, we successfully validated that nitazoxanide, a non-MDR1 substrate and the only FDA-approved drug to treat human cryptosporidiosis, killed C. parvum by fully (100%) acting on the parasite target. We also confirmed that paclitaxel acted fully on the parasite target, while several other inhibitors including mitoxantrone, doxorubicin, vincristine and ivermectin acted partially on the parasite targets. Additionally, we developed mathematical models to quantify the proportional contribution of the on-parasite-target effect to the observed anti-cryptosporidial activity and to evaluate the relationships between several in vitro parameters, including antiparasitic efficacy (ECi), cytotoxicity (TCi), selectivity index (SI) and Hill slope (h). Owning to the promiscuity of the MDR1 efflux pump, the MDR1-transgenic host cell model could be applied to assess the on-parasite-target effects of newly identified hits/leads, either substrates or non-substrates of MDR1, against Cryptosporidium or other epicellular pathogens.
微小隐孢子虫是一种分布广泛的动物源性致病原生动物寄生虫,可导致人类和动物出现中度至重度、有时甚至致命的水样腹泻,目前尚无完全有效的治疗方法。在研究针对细胞内病原体的药物作用机制时,重要的是要验证观察到的抗感染活性是归因于药物对病原体还是宿主靶标的作用。对于上皮寄生虫微小隐孢子虫,我们之前提出了一个概念,即通过瞬时过表达多药耐药蛋白 1(MDR1)使宿主细胞对多种药物具有显著的耐药性,可用于评估抑制剂对寄生虫靶标的观察到的抗隐孢子虫活性的程度和方式。然而,瞬时转染模型仅适用于评估天然 MDR1 底物。在这里,我们报告了一种使用稳定的 MDR1 转基因 HCT-8 细胞的先进模型,该模型允许通过多轮药物选择快速开发对非 MDR1 底物的新型耐药性。使用新模型,我们成功验证了硝唑尼特(一种非 MDR1 底物,也是唯一被 FDA 批准用于治疗人类隐孢子虫病的药物)通过完全(100%)作用于寄生虫靶标来杀死微小隐孢子虫。我们还证实紫杉醇完全作用于寄生虫靶标,而其他几种抑制剂,包括米托蒽醌、阿霉素、长春新碱和伊维菌素,部分作用于寄生虫靶标。此外,我们开发了数学模型来量化寄生虫靶标作用对观察到的抗隐孢子虫活性的比例贡献,并评估包括抗寄生虫疗效(ECi)、细胞毒性(TCi)、选择性指数(SI)和希尔斜率(h)在内的几个体外参数之间的关系。由于 MDR1 外排泵的混杂性,MDR1 转基因宿主细胞模型可用于评估新鉴定的针对微小隐孢子虫或其他上皮病原体的命中/先导物对寄生虫靶标的作用,这些命中/先导物要么是 MDR1 的底物,要么是非底物。